Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Rating of “Hold” by Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have earned a consensus rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $6.20.

A number of research firms have recently weighed in on STTK. HC Wainwright raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Monday, December 1st. Citigroup upped their target price on Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th. Piper Sandler initiated coverage on Shattuck Labs in a report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $3.86 on Thursday. The firm has a market cap of $244.26 million, a PE ratio of -3.78 and a beta of 1.52. The firm’s 50 day moving average price is $3.84 and its two-hundred day moving average price is $2.51. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $4.89.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors and hedge funds have recently modified their holdings of the business. Turtle Creek Wealth Advisors LLC acquired a new position in Shattuck Labs during the third quarter worth $29,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs during the 3rd quarter worth about $38,000. Squarepoint Ops LLC bought a new stake in shares of Shattuck Labs during the 3rd quarter worth about $46,000. Mallini Complete Financial Planning LLC acquired a new position in shares of Shattuck Labs during the 4th quarter valued at about $83,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Shattuck Labs in the 4th quarter valued at approximately $85,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.